Author

Sabine Ackerknecht

Institution: Idorsia Pharmaceuticals Ltd (Switzerland)

Observed institutions: Idorsia Pharmaceuticals Ltd (Switzerland), Swiss Federal Laboratories for Materials Science and Technology, Actelion (Switzerland)

OpenAlex ID: A5000217166

A high-content EMT screen identifies multiple receptor tyrosine kinase inhibitors with activity on TGFβ receptor

2016 · Carina Lotz-Jenne, Urs Lüthi, et al. · Oncotarget · 24

Discovery and binding mode of small molecule inhibitors of the apo form of human TDO2

2024 · Carina Lotz-Jenne, Roland Lange, et al. · Scientific Reports · 11

A High Throughput System for Long Term Application of Intermittent Cyclic Hydrostatic Pressure on Cells in Culture

2010 · Markus Rottmar, Sabine Ackerknecht, et al. · Journal of Biomechanical Engineering · 7

Abstract 1849: Superiority of dual IDO1/TDO2 inhibition versus IDO1 selective inhibition in reducing immunosuppressive KYN levels in tumors co-expressing IDO1 and TDO2

2023 · Carina Lotz-Jenne, Sylvaine Cren, et al. · Cancer Research · 1

Abstract B66: Superiority of dual IDO1/TDO2 inhibition versus IDO1 selective inhibition in reducing immunosuppressive KYN levels in tumors co-expressing IDO1 and TDO2

2022 · Carina Lotz-Jenne, Sylvaine Cren, et al. · Cancer Immunology Research · 1

Works count: 5

Citation count: 44

H-index: 3

I10-index: 2